FibroGen Inc. (FGEN)
NASDAQ: FGEN
· Real-Time Price · USD
11.16
-0.94 (-7.77%)
At close: Sep 08, 2025, 3:59 PM
11.86
6.27%
After-hours: Sep 08, 2025, 05:18 PM EDT
FibroGen Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Product Revenue Revenue | 1.22M | 2.6M | 3.45M | -262K | 729K | 24.49M | 1.05M | 1.32M | 14.27M | 2.11M | 6.48M | 1.09M | 7.59M | 1.13M | -8.65M | 8.48M | 686K | 8.24M |
| Drug Product Revenue Revenue Growth | -53.18% | -24.76% | -1416.41% | -135.94% | -97.02% | +2227.57% | -20.30% | -90.75% | +576.72% | -67.43% | +492.50% | -85.61% | +572.04% | -113.07% | -201.98% | +1136.15% | -91.67% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 7.06M | 8.11M | -13.32M | 17.55M | 22.28M | 16.71M | 24.22M | 25.57M | 31.18M | 34.27M | 33.97M | 29.9M | 30.26M | 30.56M | 34.74M | 25.85M | 32.55M | 30.78M | 42.25M | -48.98M | 63.53M | 49.6M | 50.71M | 35.82M | 26.74M | 22.21M | 17.85M | 15.36M | 15.05M | 15.55M | 13.85M | 12.95M | 13.43M | 11.53M | 12.59M | 11.65M | 10.38M | 11.42M | 12.96M | 11.24M | 9.68M | 10.48M |
| Selling, General, and Administrative Revenue Growth | -12.94% | -160.86% | -175.88% | -21.20% | +33.28% | -31.00% | -5.28% | -17.99% | -9.03% | +0.91% | +13.59% | -1.18% | -1.00% | -12.02% | +34.37% | -20.58% | +5.77% | -27.15% | -186.26% | -177.09% | +28.09% | -2.18% | +41.55% | +33.97% | +20.39% | +24.42% | +16.25% | +2.00% | -3.18% | +12.27% | +6.93% | -3.52% | +16.44% | -8.38% | +8.06% | +12.24% | -9.12% | -11.94% | +15.38% | +16.08% | -7.65% | n/a |
| Research and Development Revenue | 5.87M | 9.18M | 1.49M | 21.71M | 34.11M | 36.49M | 51.7M | 61.19M | 95.48M | 74.49M | 61.63M | 75.18M | 70.96M | 89.02M | 113.92M | 75.88M | 122.57M | 74.68M | 78.13M | 58.48M | 61.41M | 54.9M | 56.8M | 49.96M | 52.01M | 50.5M | 70.28M | 56.44M | 52.14M | 56.97M | 52.47M | 50.34M | 46.98M | 46.73M | 50.61M | 40.56M | 52.39M | 43.65M | 59.92M | 52.07M | 51.55M | 50.54M |
| Research and Development Revenue Growth | -36.08% | +517.43% | -93.15% | -36.35% | -6.53% | -29.43% | -15.51% | -35.91% | +28.18% | +20.86% | -18.03% | +5.95% | -20.28% | -21.86% | +50.13% | -38.09% | +64.13% | -4.42% | +33.62% | -4.78% | +11.86% | -3.34% | +13.68% | -3.93% | +2.99% | -28.15% | +24.52% | +8.26% | -8.49% | +8.59% | +4.24% | +7.14% | +0.53% | -7.66% | +24.78% | -22.59% | +20.03% | -27.16% | +15.08% | +1.00% | +2.01% | n/a |